Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Product Highlight-Victoza

27 Sep 2018
VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk

Victoza is now approved in Malaysia for prevention of
cardiovascular events.1

• The only GLP-1 proven to prevent CV events – 22% relative risk reduction in CV death2
• Unsurpassed HbA1c efficacy across 14 head-to-head trials3-6
• Unsurpassed weight loss across 14 head-to-head trials3-6


References:
1. Victoza Malaysia Prescribing Information.
2. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med.2016;375(4):311-322.
3. Pratley R, Nauck M, Bailey T, et al; for the 1860-LIRA-DPP4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes; a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397-407.
4. Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomised controlled clinical trial. Diabetes Care. 2016;39(9):1501-1509.
5. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;38(9861):117-124.
6. References on file.

Further information is available in section 11b and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.